bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 1 from A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities
Authors: Awazu Yoshiko , Nakamura Kazuhide , Mizutani Akio , Kakoi Yuichi , Iwata Hidehisa , Yamasaki Seiji , Miyamoto Naoki , Imamura Shinichi , Miki Hiroshi , Hori Akira
Published: April 2023

PDF File - 93K, Pharmacokinetic variables of T-1840383 in mice.
Supplementary Figure 3 from A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities
Authors: Awazu Yoshiko , Nakamura Kazuhide , Mizutani Akio , Kakoi Yuichi , Iwata Hidehisa , Yamasaki Seiji , Miyamoto Naoki , Imamura Shinichi , Miki Hiroshi , Hori Akira
Published: April 2023

PDF File - 203K, Effects of T-1840383 on constitutively active c-Met signaling.
Supplementary Figure 1 from A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities
Authors: Awazu Yoshiko , Nakamura Kazuhide , Mizutani Akio , Kakoi Yuichi , Iwata Hidehisa , Yamasaki Seiji , Miyamoto Naoki , Imamura Shinichi , Miki Hiroshi , Hori Akira
Published: April 2023

PDF File - 52K, Chemical structure of T-1840383 and other VEGFR or c-Met selective inhibitors.
Supplementary Figure 2 from Metabolomics Identifies Pyrimidine Starvation as the Mechanism of 5-Aminoimidazole-4-Carboxamide-1-β-Riboside-Induced Apoptosis in Multiple Myeloma Cells
Authors: Bardeleben Carolyne , Sharma Sanjai , Reeve Joseph R. , Bassilian Sara , Frost Patrick , Hoang Bao , Shi Yijiang , Lichtenstein Alan
Published: April 2023

PDF file - 1005K, IGF does not protect against AICAr induced apoptosis.
Supplementary Figures 1 through 5 from Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
Authors: Yu Peiwen , Laird A. Douglas , Du Xiangnan , Wu Jianming , Won Kwang-Ai , Yamaguchi Kyoko , Hsu Pin Pin , Qian Fawn , Jaeger Christopher T. , Zhang Wentao , Buhr Chris A. , Shen Paula , Abulafia Wendy , Chen Jason , Young Jenny , Plonowski Arthur , Yakes F. Michael , Chu Felix , Lee Michelle , Bentzien Frauke , Lam Sanh Tan , Dale Stephanie , Matthews David J. , Lamb Peter , Foster Paul
Published: April 2023

PDF - 1553K, Supplemental Figure S1: Effects of XL765 on PI3K Signaling Pathway in EGF-Stimulated PC-3 Cells. Supplemental Figure S2: Effects of XL765 on PI3K Signaling Pathway in OVCAR-3 and U87 MG cells. Supplemental Figure S3: Effects of XL765 on PI3K Pathway Signaling in A549, MDA-MB-468 and LS174T cells. Supplemental Figure S4: Anti-migratory effects of XL765 on B16 melanoma cells. Supplemental Figure S5: Body weight plots for efficacy studies shown in Figure 4.
Supplementary Table 1 from Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC
Authors: Nagel Remco , Stigter-van Walsum Marijke , Buijze Marijke , van den Berg Jaap , van der Meulen Ida H. , Hodzic Jasmina , Piersma Sander R. , Pham Thang V. , Jiménez Connie R. , van Beusechem Victor W. , Brakenhoff Ruud H.
Published: April 2023

Supplementary Table 1. Hit list genome wide siRNA screen
Supplementary Figures 1 through 4 and Supplementary Tables 1 through 3 from Involvement of microRNA-24 and DNA Methylation in Resistance of Nasopharyngeal Carcinoma to Ionizing Radiation
Authors: Wang Sumei , Zhang Rong , Claret Francois X. , Yang Huiling
Published: April 2023

Supplementary Figure 1: MiRs are expressed differently in CNE-2 and CNE-2R cells. Supplementary Figure 2: The relative percentage of methylation level between CNE-2 and CNE- 2R by cytosine-extension assay. Supplementary Figure 3: Genomic DNA methylation is altered between CNE-2 and CNE-2R cells. Supplementary Figure 4: MiR-24 promoters's CpG islands distribution. Supplementary Table 1: Information of 6 pairs NPC primary and recurrent patients. Supplementary Table 2: Radioresistant miRs signature between CNE-2 and CNE-2R. Supplementary Table 3: The numbers of genes altered on methylation between CNE-2 and CNE-2R.
Supplementary table 2 from Long Noncoding RNA ANRIL Promotes Non–Small Cell Lung Cancer Cell Proliferation and Inhibits Apoptosis by Silencing KLF2 and P21 Expression
Authors: Nie Feng-qi , Sun Ming , Yang Jin-song , Xie Min , Xu Tong-peng , Xia Rui , Liu Yan-wen , Liu Xiang-hua , Zhang Er-bao , Lu Kai-hua , Shu Yong-qian
Published: April 2023

Supplementary table 2. Univariate and multivariate analysis of overall survival in NSCLC patients (n=68)
Supplemental Table 1 from Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status
Authors: Cummings Christopher T. , Zhang Weihe , Davies Kurtis D. , Kirkpatrick Gregory D. , Zhang Dehui , DeRyckere Deborah , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , Graham Douglas K.
Published: April 2023

Supplemental Table 1: Concentration of UNC2025 in Mouse Serum and Tumors.
Supplemental Figure 2 from Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status
Authors: Cummings Christopher T. , Zhang Weihe , Davies Kurtis D. , Kirkpatrick Gregory D. , Zhang Dehui , DeRyckere Deborah , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , Graham Douglas K.
Published: April 2023

Supplemental Figure 2: UNC2025 Inhibits Survivin Expression in Various Cancer Types.
Supplemental Figure 4 from MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor
Authors: Xiao Yu , Nimmer Paul , Sheppard George S. , Bruncko Milan , Hessler Paul , Lu Xin , Roberts-Rapp Lisa , Pappano William N. , Elmore Steven W. , Souers Andrew J. , Leverson Joel D. , Phillips Darren C.
Published: April 2023

Supplemental Figure 4: BCL-XL but not BCL-2 gene silencing sensitize HCC-1806 cells to A-1210477-induced apoptosis.
Supplementary Table S1-S6 from Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody
Authors: Zhang Zheng , Zhang Yang , Sun Qian , Feng Fei , Huhe Muren , Mi Li , Chen Zhinan
Published: April 2023

Supplementary Table S1-S6. Table S1. Tissue crossreactivity of Metuzumab with different species; Table S2. Immunohistochemical Detection of CD147 by Metuzumab in Human Cancer Arrays; Table S3. Hematology analysis in rat and monkeys treated with Metuzumab in repeated dose toxicity study; Table S4. CD4+ and CD8+ T cell analysis in Cynomolgus monkey treated with Metuzumab in repeated dose toxicity study. Table S5. Clinical chemistry analysis in rats and monkeys treated with Metuzumab in repeated dose toxicity study. Table S6. CD4+ and CD8+ T cell analysis in rats treated with Metuzumab in repeated dose toxicity study.
Supplementary Table 4 from Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1–Driven Regulation of cAMP Phosphodiesterase-4D
Authors: He Ningning , Kim Nayoung , Song Mee , Park Choa , Kim Somin , Park Eun Young , Yim Hwa Young , Kim Kyunga , Park Jong Hoon , Kim Keun Il , Zhang Fan , Mills Gordon B. , Yoon Sukjoon
Published: April 2023

Supplementary Table 4: Sequence analysis to confirm the STK11 mutational status on all cell lines
Supplementary Table 1 from Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1–Driven Regulation of cAMP Phosphodiesterase-4D
Authors: He Ningning , Kim Nayoung , Song Mee , Park Choa , Kim Somin , Park Eun Young , Yim Hwa Young , Kim Kyunga , Park Jong Hoon , Kim Keun Il , Zhang Fan , Mills Gordon B. , Yoon Sukjoon
Published: April 2023

Supplementary Table 1: Categorization of 318 cancer cell lines and the occurrence of category-sensitive (and specific) gene expression markers
Supplementary Figure Legends from p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer
Authors: Tentler John J. , Ionkina Anastasia A. , Tan Aik Choon , Newton Timothy P. , Pitts Todd M. , Glogowska Magdalena J. , Kabos Peter , Sartorius Carol A. , Sullivan Kelly D. , Espinosa Joaquin M. , Eckhardt S. Gail , Diamond Jennifer R.
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 1 from Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers
Authors: Alewine Christine , Xiang Laiman , Yamori Takao , Niederfellner Gerhard , Bosslet Klaus , Pastan Ira
Published: April 2023

Supplementary Figure 1. Shows evaluation of MSLN expression in the TCGA breast cancer data set
Supplemental Figure 8 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
Authors: Theodosakis Nicholas , Held Matthew A. , Marzuka-Alcala Alexander , Meeth Katrina M. , Micevic Goran , Long Georgina V. , Scolyer Richard A. , Stern David F. , Bosenberg Marcus W.
Published: April 2023

Supplemental Figure 8. Changes in signaling upstream of translation initiation complex assembly increase out to 72 hours
Supplementary Figure 5 from The NOTCH Ligand JAGGED2 Promotes Pancreatic Cancer Metastasis Independent of NOTCH Signaling Activation
Authors: Hu Yufeng , Su Hexiu , Li Xu , Guo Guoli , Cheng Ling , Qin Renyi , Qing Guoliang , Liu Hudan
Published: April 2023

Supplementary Figure 5: Jagged1 and Jagged2-Fc are capable of inducing Notch signaling pathway.
Supplementary Figure 4 from A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation
Authors: Ott Heidi M. , Graves Alan P. , Pappalardi Melissa B. , Huddleston Michael , Halsey Wendy S. , Hughes Ashley M. , Groy Arthur , Dul Edward , Jiang Yong , Bai Yuchen , Annan Roland , Verma Sharad K. , Knight Steven D. , Kruger Ryan G. , Dhanak Dashyant , Schwartz Benjamin , Tummino Peter J. , Creasy Caretha L. , McCabe Michael T.
Published: April 2023

Supplementary Figure 4: Sanger sequencing chromatograms of EZH2 mutations in acute lymphoblastic leukemia cell lines
Data Supplement from Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α
Authors: Rossi Edmund A. , Rossi Diane L. , Cardillo Thomas M. , Chang Chien-Hsing , Goldenberg David M.
Published: April 2023

Results for analysis of (E1)-3s by SE-HPLC (Fig S1), SDS-PAGE (Fig S2), LC-MS (Fig S3) and Biacore (Fig S4).
Supplementary Figure S6 from Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells
Authors: Zhang Yan , Wang Qing , Chen Li , Yang Hsin-Sheng
Published: April 2023

Supplementary Figure S6: Over-expression of Pdcd4 inhibits OSI-906 induced phospho-P70S6K1
Supplementary Figure 2 from Radiation Protection of the Gastrointestinal Tract and Growth Inhibition of Prostate Cancer Xenografts by a Single Compound
Authors: Alexeev Vitali , Lash Elizabeth , Aguillard April , Corsini Laura , Bitterman Avi , Ward Keith , Dicker Adam P. , Linnenbach Alban , Rodeck Ulrich
Published: April 2023

Supplementary Figure 2: In vivo imaging of RTA 408-treated xenografts of human prostate cancer cells constitutively expressing firefly luciferase. Representative images of mice bearing PC3, DU145, LNCaP/C4-2B and CWR22Rv1 xenografts treated with either vehicle or RTA 408 were acquired prior to treatment (day 0) and during treatment at the time points indicated.
Supplementary Data Content from A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
Authors: Waizenegger Irene C. , Baum Anke , Steurer Steffen , Stadtmüller Heinz , Bader Gerd , Schaaf Otmar , Garin-Chesa Pilar , Schlattl Andreas , Schweifer Norbert , Haslinger Christian , Colbatzky Florian , Mousa Sien , Kalkuhl Arno , Kraut Norbert , Adolf Günther R.
Published: April 2023

Overview about Supplementary Information including brief captions
Supplementary Figure Legends from A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice
Authors: Feng Jia-Hua , Nakagawa-Goto Kyoko , Lee Kuo-Hsiung , Shyur Lie-Fen
Published: April 2023

Legends for Supplementary Figures S1-S4
Supplemental Figure 4 from Identification of Novel Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB Repair Inhibitors
Authors: Goglia Alexander G. , Delsite Robert , Luz Antonio N. , Shahbazian David , Salem Ahmed F. , Sundaram Ranjini K. , Chiaravalli Jeanne , Hendrikx Petrus J. , Wilshire Jennifer A. , Jasin Maria , Kluger Harriet M. , Glickman J. Fraser , Powell Simon N. , Bindra Ranjit S.
Published: April 2023

Counter-screen to rule out small molecule hits which may non-specifically inhibit fluorescence leading to false positive results.
Supplementary Figures from Identification of Selective Lead Compounds for Treatment of High-Ploidy Breast Cancer
Authors: Choudhary Alka , Zachek Brittany , Lera Robert F. , Zasadil Lauren M. , Lasek Amber , Denu Ryan A. , Kim Hyunjung , Kanugh Craig , Laffin Jennifer J. , Harter Josephine M. , Wisinski Kari B. , Saha Sandeep , Weaver Beth A. , Burkard Mark E.
Published: April 2023

This file contains supplementary figures S1-S4. These illustrate correlation of ploidy from chromosome 17 FSIH versus 6-chromosome FISH, chromosome spreads of cell lines, additional dose-response curves, and data demonstrating DPBQ does not operate by binding DNA or by inhibiting topoisomerase II.
Supplementary Table 3 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and mTOR Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells
Authors: Zeng Jun-Ying , Sharma Sharad , Zhou Yong-Qing , Yao Hang-Ping , Hu Xing , Zhang Ruiwen , Wang Ming-Hai
Published: April 2023

PDF - 64K, Supplementary Table 3. Minimum Inhibitory Concentrations* of BMS-777607 and Chemoagents in L3.6pl Cells and L3.6pl Cell-Derived CSCs+24/44/ESA.
Supplementary Figure S2 from Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma
Authors: Ilmer Matthias , Garnier Agnès , Vykoukal Jody , Alt Eckhard , von Schweinitz Dietrich , Kappler Roland , Berger Michael
Published: April 2023

(A) Findings of Fig. 3C are quantified by analysis of 100 randomly selected cells. Results are depicted as number of cells per 100 analyzed cells. (B) HepT1, HepG2, HuH6, and HuH7 were transfected with SuperTOP (TCF/LEF reporter) or SuperFOP (mutated TCF/LEF binding sites). Baseline Wnt activity was evaluated as ratios of TOP over FOP firefly luciferase as relative light units (RLU) normalized to renilla luciferase pRL-TK. n = 3. (C) HuH6 tumors grown in a subcutaneous in vivo model were treated with placebo or aprepitant, as previously described (1). Tumors were then subjected to qRT-PCR for LGR5, CTNNB1, and FOXM1. Whisker box plots show mean and minimum/maximum values (vehicle = 5, aprepitant treatment = 11) (D) HEK293T-7TGP cells were treated with DMSO, aprepitant (Ap), lithium chloride (LiCl) or a combination of Ap/LiCl for 24 hours and eGFP levels evaluated by flowcytometry. GFP levels (y-axis) increase upon LiCl stimulation indicating activated Wnt signaling. The latter is compromised by addition of aprepitant similar to results of (C).
Supplemental Figure Legends from ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B–Driven Brainstem Glioma Model
Authors: Mittapalli Rajendar K. , Chung Alexander H. , Parrish Karen E. , Crabtree Donna , Halvorson Kyle G. , Hu Guo , Elmquist William F. , Becher Oren J.
Published: April 2023

Supplemental Figure Legends
Figure S1 from The Role of HMGB1 in Radioresistance of Bladder Cancer
Authors: Shrivastava Sanhita , Mansure Jose Joao , Almajed Wael , Cury Fabio , Ferbeyre Gerardo , Popovic Marija , Seuntjens Jan , Kassouf Wassim
Published: April 2023

UM-UC3 and UM-UC5 HMGB1 shRNA cell line +/- recombinant HMGB1: Clonogenic Assay
Table S2 from MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Authors: Hernandez-Hoyos Gabriela , Sewell Toddy , Bader Robert , Bannink Jeannette , Chenault Ruth A. , Daugherty Mollie , Dasovich Maria , Fang Hang , Gottschalk Rebecca , Kumer John , Miller Robert E. , Ravikumar Padma , Wiens Jennifer , Algate Paul A. , Bienvenue David , McMahan Catherine J. , Natarajan Sateesh K. , Gross Jane A. , Blankenship John W.
Published: April 2023

Estimated PSMA Receptor Densities and Relative Potency of MOR209/ES414
Supplementary Figure 2 from Hypoxia-Regulated Overexpression of Soluble VEGFR2 Controls Angiogenesis and Inhibits Tumor Growth
Authors: Collet Guillaume , Lamerant-Fayel Nathalie , Tertil Magdalena , El Hafny-Rahbi Bouchra , Stepniewski Jacek , Guichard Alan , Foucault-Collet Alexandra , Klimkiewicz Krzysztof , Petoud Stéphane , Matejuk Agata , Grillon Catherine , Jozkowicz Alicja , Dulak Jozef , Kieda Claudine
Published: April 2023

PDF - 55KB, Shortening of the minCMV promoter.
Supplementary video from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro
Authors: Hoda Mir A. , Pirker Christine , Dong Yawen , Schelch Karin , Heffeter Petra , Kryeziu Kushtrim , van Schoonhoven Sushilla , Klikovits Thomas , Laszlo Viktoria , Rozsas Anita , Ozsvar Judit , Klepetko Walter , Döme Balazs , Grusch Michael , Hegedüs Balazs , Berger Walter
Published: April 2023

Trabectedin synergizes with the bcl-2 inhibitor obatoclax in a pleural mesothelioma cell model
Supporting Information from Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells
Authors: Cocco Emiliano , Deng Yang , Shapiro Erik M. , Bortolomai Ileana , Lopez Salvatore , Lin Ken , Bellone Stefania , Cui Jiajia , Menderes Gulden , Black Jonathan D. , Schwab Carlton L. , Bonazzoli Elena , Yang Fan , Predolini Federica , Zammataro Luca , Altwerger Gary , de Haydu Christopher , Clark Mitchell , Alvarenga Julio , Ratner Elena , Azodi Masoud , Silasi Dan-Arin , Schwartz Peter E. , Litkouhi Babak , Saltzman W. Mark , Santin Alessandro D.
Published: April 2023

Supporting information include 3 tables and 3 figures. Table 1 describes the Patients characteristics from which primary cell lines were established. Table 2 the characteristics of ovarian tumor samples from which RNA was extracted. Table 3 the characterization of particle formulations Supplementary figure 1 shows the DNA release in vitro in culture medium. The Supplementary figure 2 the ovarian tumors' uptake of c-CPE-NP in vivo. The Supplementary figure 3 shows the survival curves of the tumor bearing mice treated with vehicle, c-CPE-NP encapsulating the empty plasmid or the p16 DTA c-CPE-NP.
Supplementary Material and methods from Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers
Authors: Wu Zhihao , Guo Hong-Fen , Xu Hong , Cheung Nai-Kong V.
Published: April 2023

This file contains supplementary material and methods for some supplementary data
Figure S3 from Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers
Authors: Wu Zhihao , Guo Hong-Fen , Xu Hong , Cheung Nai-Kong V.
Published: April 2023

Figure S3 demonstrates the specificity of huA33-BsAb redirected killing by using control antibodies
Supplementary Table 2 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
Authors: Martini Giulia , Cardone Claudia , Vitiello Pietro Paolo , Belli Valentina , Napolitano Stefania , Troiani Teresa , Ciardiello Davide , Della Corte Carminia Maria , Morgillo Floriana , Matrone Nunzia , Sforza Vincenzo , Papaccio Gianpaolo , Desiderio Vincenzo , Paul Mariel C. , Moreno-Viedma Veronica , Normanno Nicola , Rachiglio Anna Maria , Tirino Virginia , Maiello Evaristo , Latiano Tiziana Pia , Rizzi Daniele , Signoriello Giuseppe , Sibilia Maria , Ciardiello Fortunato , Martinelli Erika
Published: April 2023

Supplementary Table 2: EPHA2 expression in tumor samples of 82 RAS WT colorectal cancer patients from the GOIM-CAPRI trial
Supplementary Figure S2 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
Authors: Buatois Vanessa , Johnson Zoë , Salgado-Pires Susana , Papaioannou Anne , Hatterer Eric , Chauchet Xavier , Richard Françoise , Barba Leticia , Daubeuf Bruno , Cons Laura , Broyer Lucile , D'Asaro Matilde , Matthes Thomas , LeGallou Simon , Fest Thierry , Tarte Karin , Clarke Hinojosa Robert K. , Genescà Ferrer Eulàlia , Ribera José María , Dey Aditi , Bailey Katharine , Fielding Adele K. , Eissenberg Linda , Ritchey Julie , Rettig Michael , DiPersio John F. , Kosco-Vilbois Marie H. , Masternak Krzysztof , Fischer Nicolas , Shang Limin , Ferlin Walter G.
Published: April 2023

Supplementary Figure S2 shows in vitro hemagglutination in human or cynomolgus monkeys whole blood, or platelet aggregation in human platelet rich-plasma (PRP)in presence of NI-1701
Supplementary Table 4 from Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies
Authors: Shatsky Rebecca , Parker Barbara A. , Bui Nam Q. , Helsten Teresa , Schwab Richard B. , Boles Sarah G , Kurzrock Razelle
Published: April 2023

This table shows the alterations detected in ctDNA and tissue NGS.
Supplementary Table 1 from Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies
Authors: Shatsky Rebecca , Parker Barbara A. , Bui Nam Q. , Helsten Teresa , Schwab Richard B. , Boles Sarah G , Kurzrock Razelle
Published: April 2023

This table shows the 54 gene panel (ctDNA).
Table S1 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Authors: Hao Huai-Xiang , Wang Hongyun , Liu Chen , Kovats Steven , Velazquez Roberto , Lu Hengyu , Pant Bhavesh , Shirley Matthew , Meyer Matthew J. , Pu Minying , Lim Joanne , Fleming Michael , Alexander LeighAnn , Farsidjani Ali , LaMarche Matthew J. , Moody Susan , Silver Serena J. , Caponigro Giordano , Stuart Darrin D. , Abrams Tinya J. , Hammerman Peter S. , Williams Juliet , Engelman Jeffrey A. , Goldoni Silvia , Mohseni Morvarid
Published: April 2023

Supplementary Table 1: List of all cell lines in the CCLE (Cancer Cell Line Encyclopedia) where sensitivity to SHP2 (PTPN11) knockdown was evaluated in 2D. Lineage, and genetic status of KRAS and BRAF are shown. Blank cells represent cell line data where genetic or sensitivity data do not exist. Values depicted are the ATARIS quantile normalized z-score. Additional details on the methodology of the screen are published (58).
Figure S2 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Authors: Hao Huai-Xiang , Wang Hongyun , Liu Chen , Kovats Steven , Velazquez Roberto , Lu Hengyu , Pant Bhavesh , Shirley Matthew , Meyer Matthew J. , Pu Minying , Lim Joanne , Fleming Michael , Alexander LeighAnn , Farsidjani Ali , LaMarche Matthew J. , Moody Susan , Silver Serena J. , Caponigro Giordano , Stuart Darrin D. , Abrams Tinya J. , Hammerman Peter S. , Williams Juliet , Engelman Jeffrey A. , Goldoni Silvia , Mohseni Morvarid
Published: April 2023

In vivo efficacy of SHP099 (100 mg/kg, daily) in the KYSE-520 esophageal cancer cell line model. Data are plotted as the treatment mean {plus minus} s.e.m (n=7) ( (B-I) In vivo efficacy data for cell line models represented in Fig. 3E. SHP099 and trametinib were orally administered at the doses, schedules and for the duration indicated. Data are plotted as the treatment mean {plus minus} s.e.m.
Supplementary figure 3 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
Authors: Guichard Sylvie M. , Curwen Jon , Bihani Teeru , D'Cruz Celina M. , Yates James W.T. , Grondine Michael , Howard Zoe , Davies Barry R. , Bigley Graham , Klinowska Teresa , Pike Kurt G. , Pass Martin , Chresta Christine M. , Polanska Urszula M. , McEwen Robert , Delpuech Oona , Green Stephen , Cosulich Sabina C.
Published: April 2023

Pharmacokinetics modelling of AZD2014 intermittent dosing schedule.
Supplemental Materials and Methods from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Authors: Whalen Kerry A. , White Brian H. , Quinn James M. , Kriksciukaite Kristina , Alargova Rossitza , Au Yeung Tsun P. , Bazinet Patrick , Brockman Adam , DuPont Michelle M. , Oller Haley , Gifford James , Lemelin Charles-Andre , Lim Soo Patrick , Perino Samantha , Moreau Benoît , Sharma Gitanjali , Shinde Rajesh , Sweryda-Krawiec Beata , Bilodeau Mark T. , Wooster Richard
Published: April 2023

Description of BT-984 synthesis and LC-MS/MS sample preparation
Table S1 from PD-1/PD-L1 Immune Checkpoint Inhibition with Radiation in Bladder Cancer: In Situ and Abscopal Effects
Authors: Rompré-Brodeur Alexis , Shinde-Jadhav Surashri , Ayoub Mina , Piccirillo Ciriaco A. , Seuntjens Jan , Brimo Fadi , Mansure Jose Joao , Kassouf Wassim
Published: April 2023

Complete gene list in the qPCR kit and respective expression fold changes per experimental condition
Supplemental Figure 2 from Fenretinide, Tocilizumab, and Reparixin Provide Multifaceted Disruption of Oral Squamous Cell Carcinoma Stem Cell Properties: Implications for Tertiary Chemoprevention
Authors: Mallery Susan R. , Wang Daren , Santiago Brian , Pei Ping , Bissonnette Caroline , Jayawardena Jayanetti Asiri , Schwendeman Steven P. , Spinney Richard , Lang James
Published: April 2023

Paclitaxel optimization for stem cell selection studies
Supplemental Figure 1 from Fenretinide, Tocilizumab, and Reparixin Provide Multifaceted Disruption of Oral Squamous Cell Carcinoma Stem Cell Properties: Implications for Tertiary Chemoprevention
Authors: Mallery Susan R. , Wang Daren , Santiago Brian , Pei Ping , Bissonnette Caroline , Jayawardena Jayanetti Asiri , Schwendeman Steven P. , Spinney Richard , Lang James
Published: April 2023

Histopathologic differences between non-HPV and HPV OSCC tumors
Supplementary Figure S2 from A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition
Authors: Kim Eun Hye , Jang Hyejin , Roh Jong-Lyel
Published: April 2023

Supplementary Figure S2. Selective killing effect of DPP-23 on HNC cells but not normal cells. The cell growth were measured with trypan blue exclusion assay after exposure to DPP-23 for 72 h.
Supplementary Figure S2 from Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63
Authors: de Goeij Bart E.C.G. , Vink Tom , ten Napel Hendrik , Breij Esther C.W. , Satijn David , Wubbolts Richard , Miao David , Parren Paul W.H.I.
Published: April 2023

Lysosomal transport of a bispecific antibody targeting integrin-β1 and CD63
Figure S6 from Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
Authors: Santoro Raffaela , Zanotto Marco , Simionato Francesca , Zecchetto Camilla , Merz Valeria , Cavallini Chiara , Piro Geny , Sabbadini Fabio , Boschi Federico , Scarpa Aldo , Melisi Davide
Published: April 2023

Figure S6 shows: (A) Anchorage-independent cell growth of AsPC1shTAK1, Panc1shTAK1 and MDA-Panc28shTAK1 cells either treated or not with LY2090314 3μM for 72 hours, and allowed to form spheroids in ultra-low attachment plates. Histograms show spheroids diameter.(B) AsPC1shTAK1, Panc1shTAK1 and MDA-Panc28shTAK1 cells were seeded and either treated or not with LY2090314 3μM for 72 hours. Cells were then counted and seeded into the upper chamber of a transwell. Histograms show the percentage of migrated cells.
Supplementary Movie S3 from Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer
Authors: Ludwik Katarzyna A. , Campbell J. Preston , Li Mingzong , Li Yu , Sandusky Zachary M. , Pasic Lejla , Sowder Miranda E. , Brenin David R. , Pietenpol Jennifer A. , O'Doherty George A. , Lannigan Deborah A.
Published: April 2023

Scratch assay using HDQ-P1 cells. Top vehicle, bottom (1b) (50 μM) over a 10h time frame.
Supplementary Figure 6 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment
Authors: Rosas-Plaza Ximena , de Vries Gerda , Meersma Gert Jan , Suurmeijer Albert J.H. , Gietema Jourik A. , van Vugt Marcel A.T.M. , de Jong Steven
Published: April 2023

mTORC1/2 inhibition in combination with cisplatin in TC PDX models
Supplemental Figures S1-S5 from Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts
Authors: Chen Nancy E. , Maldonado N. Vanessa , Khankaldyyan Vazgen , Shimada Hiroyuki , Song Michael M. , Maurer Barry J. , Reynolds C. Patrick
Published: April 2023

Supplementary Figure S1: Tumor growth curves for individual mouse xenografts treated with 4-HPR/LXS and ABT-751; Supplementary Figure S2: Dose escalation study of n-acetylcysteine (NAC) and sodium thiosulfate (STS); Supplementary Figure S3: Effect of 4-HPR + ABT-751 on mitochondrial membrane depolarization, cytochrome c release, and caspase and poly (ADPribose) polymerase (PARP) cleavage; Supplementary Figure S4: Cytotoxicities of fenretinide(4-HPR) in combination with five microtubule inhibitors in three neuroblastoma cell lines (SMS-KCNR, CHLA-119, and CHLA-140); Supplementary Figure S5: Effect of the antioxidants vitamin C (Vit C) and vitamin E (Vit E) on the cytotoxiciity of fenretinide (4-HPR) in combination with five microtubule inhibitors in two neuroblastoma cell lines.
Supplementary Figure 3 from Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
Authors: Flem-Karlsen Karine , McFadden Erin , Omar Nasrin , Haugen Mads H. , Øy Geir Frode , Ryder Truls , Gullestad Hans Petter , Hermann Robert , Mælandsmo Gunhild Mari , Flørenes Vivi Ann
Published: April 2023

Supplementary Figure 3 shows cell cycle profiles for Melmet 1 and WM1366 cells and YH2AX expression measured by flow cytometry for WM1366 cells. Further, the figure shows immunoblots of indicated proteins for cells treated with BGB324 and/or AZD7762 or BGB324 and/or VE-822.
Supplementary Data from Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies
Authors: Lu Haihui , Molony Ryan D. , Chen Dongshu , Jang Sunyoung , Wolf Babette , Ewert Stefan , Flaherty Meghan , Xu Fangmin , Isim Sinan , Shim Yeonju , Dornelas Christina , Balke Nicole , Leber Xavier Charles , Scharenberg Meike , Koelln Johanna , Choi Eugene , Ward Rebecca , Johnson Jennifer , Calzascia Thomas , Isnardi Isabelle , Williams Juliet A. , Lindenbergh Pieter L. , van de Donk Niels W.C.J. , Mutis Tuna , Huet Heather , Lees Emma , Meyer Matthew J.
Published: April 2023

Supplementary Materials and Methods, Tables
Figure S1 from Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic β-catenin Signaling and EMT Progression
Authors: Hafeez Bilal Bin , Ganju Aditya , Sikander Mohammed , Kashyap Vivek K. , Hafeez Zubair Bin , Chauhan Neeraj , Malik Shabnam , Massey Andrew E. , Tripathi Manish K. , Halaweish Fathi T. , Zafar Nadeem , Singh Man M. , Yallapu Murali M. , Chauhan Subhash C. , Jaggi Meena
Published: April 2023

Effect of ORM on proliferation of various human PrCa cell lines as determined by counting the cells.
Supplementary Table 1 from Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5
Authors: Le Gall Marianne , Crépin Ronan , Neiveyans Madeline , Auclair Christian , Fan Yongfeng , Zhou Yu , Marks James D. , Pèlegrin André , Poul Marie-Alix
Published: April 2023

Monitoring of phage antibody selection by titration, ELISA and scFv sequencing.
Table S2 from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
Authors: Manara Maria Cristina , Valente Sergio , Cristalli Camilla , Nicoletti Giordano , Landuzzi Lorena , Zwergel Clemens , Mazzone Roberta , Stazi Giulia , Arimondo Paola B. , Pasello Michela , Guerzoni Clara , Picci Piero , Nanni Patrizia , Lollini Pier-Luigi , Mai Antonello , Scotlandi Katia
Published: April 2023

Osteogenesis RT2 Profiler TM PCR Array in Saos-2 cell line after 7 and 14 days of induced osteogenesis and DNMT inhibitors treatment
Supplementary Tables S1, S2, S5, and S7 from Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing
Authors: Das Sunetra , Idate Rupa , Cronise Kathryn E. , Gustafson Daniel L. , Duval Dawn L.
Published: April 2023

Supplementary Table S1A. Metadata associated with canine cancer cell line panel. Supplementary Table S1B. Metadata associated with normal samples. Supplementary Table S2. Certificate of Analysis - Cell Line Validation. Supplementary Table S5. List of protein coding somatic variants identified in 33 canine cancer cell lines. Supplementary Table S7. Functional clustering of genes into selected categories.
Supplementary Figs. S1 - S6 from Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing
Authors: Das Sunetra , Idate Rupa , Cronise Kathryn E. , Gustafson Daniel L. , Duval Dawn L.
Published: April 2023

Supplementary Fig. S1. Pipeline for post-processing of somatic variants. Supplementary Fig. S2. Distribution of genes and variants. Supplementary Fig. S3. MDM2 and TP53 transcript levels. Supplementary Fig. S4. KEGG MAPK pathway. Supplementary Fig. S5. KEGG PI3K-AKT pathway. Supplementary Fig. S6 Western blot analyses for ERK/pERK and AKT/pAKT.
Supplemental Figure 3 from CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer
Authors: Xiang Jingyu , Hurchla Michelle A. , Fontana Francesca , Su Xinming , Amend Sarah R. , Esser Alison K. , Douglas Garry J. , Mudalagiriyappa Chidananda , Luker Kathryn E. , Pluard Timothy , Ademuyiwa Foluso O. , Romagnoli Barbara , Tuffin Gérald , Chevalier Eric , Luker Gary D. , Bauer Michael , Zimmermann Johann , Aft Rebecca L. , Dembowsky Klaus , Weilbaecher Katherine N.
Published: April 2023

Supplemental Figure 3. Gaussia luciferase complementation imaging model and scratch migration assay with AMD3100.
Supplementary Figure S5 from ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine
Authors: Bhagwat Shripad V. , McMillen William T. , Cai Shufen , Zhao Baohui , Whitesell Matthew , Shen Weihua , Kindler Lisa , Flack Robert S. , Wu Wenjuan , Anderson Bryan , Zhai Yan , Yuan Xiu-Juan , Pogue Meghann , Van Horn Robert D. , Rao Xi , McCann Denis , Dropsey Andrew J. , Manro Jason , Walgren Jennie , Yuen Eunice , Rodriguez Michael J. , Plowman Gregory D. , Tiu Ramon V. , Joseph Sajan , Peng Sheng-Bin
Published: April 2023

In vivo effect of treatment on body weight loss.
Supplementary Table 3 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
Authors: Miller Rowan E. , Brough Rachel , Bajrami Ilirjana , Williamson Chris T. , McDade Simon , Campbell James , Kigozi Asha , Rafiq Rumana , Pemberton Helen , Natrajan Rachel , Joel Josephine , Astley Holly , Mahoney Claire , Moore Jonathan D. , Torrance Chris , Gordan John D. , Webber James T. , Levin Rebecca S. , Shokat Kevan M. , Bandyopadhyay Sourav , Lord Christopher J. , Ashworth Alan
Published: April 2023

Additional compounds included in the isogenic high-throughput drug screen
Supplementary Table S1 from Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies
Authors: Azuara Daniel , Santos Cristina , Lopez-Doriga Adriana , Grasselli Julieta , Nadal Marga , Sanjuan Xavier , Marin Fátima , Vidal Joana , Montal Robert , Moreno Victor , Bellosillo Beatriz , Argiles Guillem , Elez Elena , Dienstmann Rodrigo , Montagut Clara , Tabernero Josep , Capellá Gabriel , Salazar Ramon
Published: April 2023

Primers and conditions of PCR amplicons
Supplementary Figure 1 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo
Authors: Staudacher Alexander H. , Li Yanrui , Liapis Vasilios , Hou Jeff Jia Cheng , Chin David , Dolezal Olan , Adams Timothy E. , van Berkel Patrick H. , Brown Michael P.
Published: April 2023

Chemical structure of MC-PEG4-VC-PAB-Duocarmycin DM, and chDAB4 binding and phagocytosis of dead tumour cells treated with ADC drugs.
Supplementary Table S1 from Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Authors: Andreev Julian , Thambi Nithya , Perez Bay Andres E. , Delfino Frank , Martin Joel , Kelly Marcus P. , Kirshner Jessica R. , Rafique Ashique , Kunz Arthur , Nittoli Thomas , MacDonald Douglas , Daly Christopher , Olson William , Thurston Gavin
Published: April 2023

Surface Plasmon Resonance (SRP)-derived binding affinities and kinetic constants of HER2(T)xPRLR and its parental antibodies: HER2 antibody and H1H7672P2.
Figure S2 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
Authors: Pradel Leon P. , Ooi Chia-Huey , Romagnoli Solange , Cannarile Michael A. , Sade Hadassah , Rüttinger Dominik , Ries Carola H.
Published: April 2023

Correlation of certain epidemiological factors to a large donor cohort treated with RG7155
Supplementary Materials and Methods from Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
Authors: Ardini Elena , Menichincheri Maria , Banfi Patrizia , Bosotti Roberta , De Ponti Cristina , Pulci Romana , Ballinari Dario , Ciomei Marina , Texido Gemma , Degrassi Anna , Avanzi Nilla , Amboldi Nadia , Saccardo Maria Beatrice , Casero Daniele , Orsini Paolo , Bandiera Tiziano , Mologni Luca , Anderson David , Wei Ge , Harris Jason , Vernier Jean-Michel , Li Gang , Felder Eduard , Donati Daniele , Isacchi Antonella , Pesenti Enrico , Magnaghi Paola , Galvani Arturo
Published: April 2023

Supplementary experimental procedures are described
Supplemental Table 2 from Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R
Authors: de Lint Klaas , Poell Jos B. , Soueidan Hayssam , Jastrzebski Katarzyna , Vidal Rodriguez Jordi , Lieftink Cor , Wessels Lodewyk F.A. , Beijersbergen Roderick L.
Published: April 2023

RNAseq read counts of IGF1R related genes in the TNBC cell line panel
Supplemental Table 4 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Authors: Thibault Stephane , Hu Wenyue , Hirakawa Brad , Kalabat Dalia , Franks Tania , Sung Tae , Khoh-Reiter Su , Lu Shuyan , Finkelstein Martin , Jessen Bart , Sacaan Aida
Published: April 2023

Table S4 shows expression change in solute carrier family genes.
Supplemental Table 3 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Authors: Thibault Stephane , Hu Wenyue , Hirakawa Brad , Kalabat Dalia , Franks Tania , Sung Tae , Khoh-Reiter Su , Lu Shuyan , Finkelstein Martin , Jessen Bart , Sacaan Aida
Published: April 2023

Table S3 shows A: Most significantly impacted pathways. B: Most significantly impacted upstream regulators.
Supplemental Figure 3 and legend from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Authors: Thibault Stephane , Hu Wenyue , Hirakawa Brad , Kalabat Dalia , Franks Tania , Sung Tae , Khoh-Reiter Su , Lu Shuyan , Finkelstein Martin , Jessen Bart , Sacaan Aida
Published: April 2023

Figure S3 shows Axin2 expression normalized to vehicle.
Supplementary Figure 2 from Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma
Authors: Ilhan-Mutlu Aysegül , Osswald Matthias , Liao Yunxiang , Gömmel Miriam , Reck Martin , Miles David , Mariani Paola , Gianni Luca , Lutiger Beatrix , Nendel Viktor , Srock Stefanie , Perez-Moreno Pablo , Thorsen Frits , von Baumgarten Louisa , Preusser Matthias , Wick Wolfgang , Winkler Frank
Published: April 2023

Percentage growth change of individual nsNSCLC metastases during bevacizumab treatment
Supplemental Figure Legends from Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
Authors: Bisi John E. , Sorrentino Jessica A. , Roberts Patrick J. , Tavares Francis X. , Strum Jay C.
Published: April 2023

Supplemental Figure Legends
Supplementary Table 1 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
Authors: Onion David , Argent Richard H. , Reece-Smith Alexander M. , Craze Madeleine L. , Pineda Robert G. , Clarke Philip A. , Ratan Hari L. , Parsons Simon L. , Lobo Dileep N. , Duffy John P. , Atherton John C. , McKenzie Andrew J. , Kumari Rajendra , King Peter , Hall Brett M. , Grabowska Anna M.
Published: April 2023

Achievable peak serum concentration of chemotherapies in humans and associated references.
Supplementary Figure 5 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
Authors: Onion David , Argent Richard H. , Reece-Smith Alexander M. , Craze Madeleine L. , Pineda Robert G. , Clarke Philip A. , Ratan Hari L. , Parsons Simon L. , Lobo Dileep N. , Duffy John P. , Atherton John C. , McKenzie Andrew J. , Kumari Rajendra , King Peter , Hall Brett M. , Grabowska Anna M.
Published: April 2023

HGF expression in CAFS and MSCs.
Supplementary Figure S3 from Simvastatin-Induced Apoptosis in Osteosarcoma Cells: A Key Role of RhoA-AMPK/p38 MAPK Signaling in Antitumor Activity
Authors: Kamel Walied A. , Sugihara Eiji , Nobusue Hiroyuki , Yamaguchi-Iwai Sayaka , Onishi Nobuyuki , Maki Kenta , Fukuchi Yumi , Matsuo Koichi , Muto Akihiro , Saya Hideyuki , Shimizu Takatsune
Published: April 2023

(A, B) Weight of AXT cell-derived tumors formed in mice treated with saline or simvastatin administered either by intraperitoneal injection (40 mg/kg per day) (A) or by oral gavage (80 mg/kg per day) (B) Data are means {plus minus} SD. (C) Viability of AXT cells treated with the indicated concentrations of TOFA for 1 or 2 days. (D) Weight of AXT cell-derived tumors at 3 weeks after cell injection in mice fed a normal or fat-free diet. The fat-free diet was initiated 4 days before cell injection. Data are means {plus minus} SD. (E) Model for the mechanism of apoptosis induction by simvastatin.
Movie S1: Cell body tracking of MDA-MB-231LN treated with MLN8237 and/or eribulin during collagen invasion from Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer
Authors: Kozyreva Varvara K. , Kiseleva Anna A. , Ice Ryan J. , Jones Brandon C. , Loskutov Yuriy V. , Matalkah Fatimah , Smolkin Matthew B. , Marinak Kristina , Livengood Ryan H. , Salkeni Mohamad A. , Wen Sijin , Hazard Hannah W. , Layne Ginger P. , Walsh Callee M. , Cantrell Pamela S. , Kilby Greg W. , Mahavadi Sricharan , Shah Neal , Pugacheva Elena N.
Published: April 2023

Representative movie of individual MDA-MB-231LN cells treated with Vehicle, MLN8237, eribulin, or MLN8237/eribulin combination, suspended in collagen, and manually tracked over the course of 23 hours toward the serum chemoattractant-containing reservoir (left side of frame).
Supplemental Figure S1-S2 from Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer
Authors: Liu Chengfei , Armstrong Cameron M. , Lou Wei , Lombard Alan P. , Cucchiara Vito , Gu Xinwei , Yang Joy C. , Nadiminty Nagalakshmi , Pan Chong-xian , Evans Christopher P. , Gao Allen C.
Published: April 2023

Supplemental Fig.1. Bicalutamide and AR-V7 knockdown combination suppressed PSA luciferase activity; Supplemental Fig.2. Niclosamide and bicalutamide combination treatment suppressed AR and AR-V7 target genes expression in C4-2B MDVR cells.
Supplementary methods from Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer
Authors: Boukalova Stepana , Stursa Jan , Werner Lukas , Ezrova Zuzana , Cerny Jiri , Bezawork-Geleta Ayenachew , Pecinova Alena , Dong Lanfeng , Drahota Zdenek , Neuzil Jiri
Published: April 2023

This file contains supplementary methods
Supplementary legends from Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy
Authors: Kim Jeffrey , Ulu Arzu , Wan Debin , Yang Jun , Hammock Bruce D , Weiss Robert H.
Published: April 2023

Supplementary legends
Supplementary Fig. 1 from Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma
Authors: Han Hee Dong , Cho Young-Jae , Cho Sung Keun , Byeon Yeongseon , Jeon Hat Nim , Kim Hye-Sun , Kim Byoung-Gie , Bae Duk-Soo , Lopez-Berestein Gabriel , Sood Anil K. , Shin Byung Cheol , Park Yeong-Min , Lee Jeong-Won
Published: April 2023

Safety and toxicity in mouse after treatment of linalool with different dose.
Supplementary Figure 1 from Photodynamic Therapy Using Photosensitizer-Encapsulated Polymeric Nanoparticle to Overcome ATP-Binding Cassette Transporter Subfamily G2 Function in Pancreatic Cancer
Authors: Roh Yoon Jin , Kim Ju Hee , Kim In-Wook , Na Kun , Park Jae Myung , Choi Myung-Gyu
Published: April 2023

Structure of Chlorin e6 (A) and Photosensitizer-encapsulated Polymeric Nanoparticle (B).
Figure S5 from Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2
Authors: Weiswald Louis-Bastien , Hasan Mohammad R. , Wong John C.T. , Pasiliao Clarissa C. , Rahman Mahbuba , Ren Jianhua , Yin Yaling , Gusscott Samuel , Vacher Sophie , Weng Andrew P. , Kennecke Hagen F. , Bièche Ivan , Schaeffer David F. , Yapp Donald T. , Tai Isabella T.
Published: April 2023

Effects of CDK10 expression on Aurora Kinase A expression. Immunoblot of Aurora Kinase A in CDK10 overexpressing RKO and MIP101 cells.
Supplementary Figure S2 from Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017
Authors: Uitdehaag Joost C.M. , Kooijman Jeffrey J. , de Roos Jeroen A.D.M. , Prinsen Martine B.W. , Dylus Jelle , Willemsen-Seegers Nicole , Kawase Yusuke , Sawa Masaaki , de Man Jos , van Gerwen Suzanne J.C. , Buijsman Rogier C. , Zaman Guido J.R.
Published: April 2023

Workflow for identification and validation of predictive drug response biomarkers based on gene expression